Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 4,835 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy Subject, Pancreatic Carcinoma
Interventions
Computed Tomography, Laboratory Biomarker Analysis, PET/MRI scan, [18F]FP-R01-MG-F2
Diagnostic Test · Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Healthy Volunteers
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
20 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

NCT01493596
Conditions
Cocaine Dependency
Interventions
CPP-115, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Aging, Facial Aging
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Minimally Invasive Biomarker for Asthma Disease Severity

NCT02225678
Conditions
Asthma, Healthy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Heathy Volunteer
Interventions
CC-90001, Omeprazole, Midazolam, Warfarin, Vitamin K, Rosuvastatin, Metformin, Digoxin, Nintedanib
Drug · Dietary Supplement
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Gastrointestinal Symptoms
Interventions
Prog: Purify-2
Other
Lead sponsor
Nature's Sunshine Products, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lehi, Utah
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Lubiprostone and Mucus Secretion in Patients With Chronic Constipation

NCT01447849
Conditions
Constipation
Interventions
lubiprostone, placebo
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
El Paso, Texas
Conditions
Tolerance
Interventions
1 serving of test product, 2 servings of test product, 3 servings of test product, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Healthy
Interventions
Azithromycin Tablets 600 mg, Zithromax® Tablets 600 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Metformin 500 mg q12h, Dolutegravir 50 mg q24h, Dolutegravir 50 mg q12h
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Opioid-Related Disorders
Interventions
Nalmefene
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Healthy
Interventions
ZD4054
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

NCT02620774
Conditions
Diabetes, Wound Infection, Healthy Volunteers
Interventions
Ceftolozane/tazobactam, Microdialysis Catheter Insertion
Drug · Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hartford, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

NCT01688297
Conditions
Influenza
Interventions
VXA-A1.1 Oral Vaccine, VXA Placebo Tablet
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cypress, California
Conditions
Healthy Volunteers
Interventions
Supplement
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Healthy Volunteers
Interventions
Branebrutinib, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Conditions
Healthy
Interventions
Ortho-Cyclen, AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Conditions
Healthy
Interventions
NM8074, Placebo
Drug
Lead sponsor
NovelMed Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Extraocular Retinoblastoma, Intraocular Retinoblastoma, Recurrent Retinoblastoma
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
49
States / cities
Los Angeles, California • Madera, California • San Francisco, California + 38 more
Conditions
Healthy
Interventions
AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Conditions
Healthy Volunteers
Interventions
Caplacizumab Dose 1 iv (single-dose), Caplacizumab Dose 2 iv (single-dose), Caplacizumab Dose 2 sc (single-dose), Caplacizumab Dose 2 sc (multiple-dose), Placebo iv (single-dose), Placebo sc (single-dose), Placebo sc (multiple-dose)
Biological · Other
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2256294, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy Volunteers
Interventions
Midazolam, Repaglinide, TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona